Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
Caregiver Burnout During Lu-177 PSMA Therapy
Caring for a loved one on Lu-177 PSMA therapy for mCRPC is more demanding than most people expect. This article helps spouses and adult children recognize caregiver burnout, follow radiation safety rules at home, and sustain their own health through treatment.
Lu-177 PSMA Resistance and Next Steps for mCRPC
If lutetium Lu-177 PSMA therapy has stopped controlling your metastatic castration-resistant prostate cancer, you still have options. This article explains why resistance happens, how your team identifies it, and what the next treatment paths may look like.
Financing Your Lu-177 PSMA Treatment in India
In the United States, a full course of Pluvicto can exceed USD 250,000 in drug costs alone. This guide covers the medical tourism loans, hospital payment plans, and employer schemes that patients with mCRPC use to finance Lu-177 PSMA therapy in India.
Will PRRT Control Your Carcinoid Syndrome Symptoms?
Carcinoid syndrome - flushing, diarrhea, and abdominal cramps driven by hormone-producing GEP-NETs - can persist even on somatostatin analogues. Research shows that PRRT using lutetium Lu-177 dotatate may reduce these hormone-driven symptoms alongside slowing tumour growth.
Lu-177 PSMA Eligibility With Declining Kidney Function
Declining kidney function is one of the most common concerns men raise before starting Lu-177 PSMA therapy. This article explains how kidney health is assessed, what GFR thresholds mean in practice, and what options remain when kidney numbers are borderline or low.
Planning Your India Trip for Lu-177 PSMA Therapy
If your PSMA-PET scan confirms eligibility and India is on your radar, this guide covers the practical side: visas, flights, accommodation, and what to budget beyond the treatment cost itself.
PRRT in India: Real Travel Costs for International Patients
Traveling to India for PRRT? This guide breaks down what international NET patients actually spend on treatment, flights, visas, accommodation, and insurance - so you can build a realistic budget before you book anything.
Lu-177 PSMA vs Taxane Chemotherapy After Hormone Failure
When hormone therapy stops working in metastatic prostate cancer, two main options emerge: Lu-177 PSMA radioligand therapy and taxane chemotherapy. Which path fits your case depends on one factor above all others - whether your tumors show PSMA expression on a PET scan.
Grade 1 NET and PRRT: When Lu-177 DOTATATE Can Wait
If your GEP-NET is Grade 1 and your disease is stable, PRRT with lutetium Lu-177 dotatate may not be the right next step yet. Learn what the evidence says about timing PRRT for low-grade neuroendocrine tumors - and when a Grade 1 NET does cross the threshold for treatment.
When PSMA Imaging Is Negative in mCRPC: Lu-177 Eligibility Explained
Your PSA is climbing, but your scans show nothing. Learn why PSMA-PET imaging is the gating test for Lu-177 PSMA therapy, what a negative scan actually means, and what options remain in mCRPC.
Lu-177 PSMA Caregiver Guide for mCRPC Families
If your husband, father, or partner is starting lutetium Lu-177 PSMA therapy for metastatic castration-resistant prostate cancer, this guide explains the radiation safety rules you must follow at home, which side effects to watch for between cycles, and how to protect your own health across a treatment course that may run six months or longer.
Preparing for Your PSMA PET Scan for Lu-177 Eligibility
A PSMA PET scan is the test that determines whether Lu-177 PSMA therapy may be an option for your metastatic prostate cancer. This guide covers how to prepare, what happens during imaging, and what your results mean for eligibility.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.